Patents Assigned to NBE Therapeutics AG
  • Anthracycline-based antibody drug conjugates having high in vivo tolerability
    Patent number: 12121527
    Abstract: The present invention relates to antibody drug conjugates (ADCs) presenting improved properties of in vivo tolerability.
    Type: Grant
    Filed: July 10, 2020
    Date of Patent: October 22, 2024
    Assignee: NBE-THERAPEUTICS AG
    Inventors: Ulf Grawunder, Roger Beerli, Remy Gebleux
  • Method of producing an immunoligand/payload conjugate
    Patent number: 11986535
    Abstract: The present invention relates to a method of producing an immunoligand/payload conjugate, which method encompasses conjugating a payload to an immunoligand by means of a sequence-specific transpeptidase, or a catalytic domain thereof (Fig. 6b).
    Type: Grant
    Filed: June 13, 2022
    Date of Patent: May 21, 2024
    Assignee: NBE THERAPEUTICS AG
    Inventors: Ulf Grawunder, Roger Renzo Beerli
  • Anti-ROR1 antibodies
    Patent number: 11845793
    Abstract: The present invention relates to a human or humanized antibody, or an antibody-based binding protein, modified antibody format retaining target binding capacity, antibody derivative or fragment retaining target binding capacity, which targets Receptor tyrosine kinase-like orphan receptor-1 (ROR1). It further relates to bi- or multispecific antibodies, to Immunoligand-Drug Conjugates, to Chimeric Antigen Receptors and to T-cells comprising such Chimeric Antigen Receptors.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: December 19, 2023
    Assignee: NBE-THERAPEUTICS AG
    Inventors: Lorenz Waldmeier, Ulf Grawunder, Roger Beerli
  • Binding protein drug conjugates comprising anthracycline derivatives
    Patent number: 11833120
    Abstract: The present invention relates to an anthracycline (PNU) derivative conjugate comprising a derivative of the anthracycline PNU-159682.
    Type: Grant
    Filed: February 25, 2021
    Date of Patent: December 5, 2023
    Assignee: NBE-THERAPEUTICS AG
    Inventors: Ulf Grawunder, Roger Renzo Beerli
  • Human antibodies binding to ROR2
    Patent number: 11447546
    Abstract: The present invention relates to fully human antibodies and conjugates thereof, which specifically bind to the extracellular domain of receptor tyrosine kinase-like orphan receptor 2 (ROR2).
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: September 20, 2022
    Assignee: NBE-THERAPEUTICS AG
    Inventors: Ulf Grawunder, Roger Beerli, Ina Hellmann, Lorenz Waldmeier
  • Method of producing an immunoligand/payload conjugate
    Patent number: 11364301
    Abstract: The present invention relates to a method of producing an immunoligand/payload conjugate, which method encompasses conjugating a payload to an immunoligand by means of a sequence-specific transpeptidase, or a catalytic domain thereof (FIG. 6B).
    Type: Grant
    Filed: June 29, 2020
    Date of Patent: June 21, 2022
    Assignee: NBE-THERAPEUTICS AG
    Inventors: Ulf Grawunder, Roger Renzo Beerli
  • ROR1 antibody compositions and related methods
    Patent number: 11242388
    Abstract: The invention provides antibodies, antibody drug conjugates, antibody-based fragments or antibody fragments (antigen-binding fragments), as well as antibody drug conjugates (ADCs) and chimeric antigen receptors (CARs), that specifically recognize human ROR1 and related compositions. Also provided in the invention are methods of using such antibodies in various diagnostic and therapeutic applications.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: February 8, 2022
    Assignees: NBE-Therapeutics AG, The Scripps Research Institute
    Inventors: Christoph Rader, Haiyong Peng, Roger Beerli, Lorenz Waldmeier, Ulf Grawunder
  • Binding protein drug conjugates comprising anthracycline derivatives
    Patent number: 10960083
    Abstract: The present invention relates to an anthracycline (PNU) derivative conjugate comprising a derivative of the anthracycline PNU-159682 having the formula (i) or formula (ii) which further comprises a linker structure X-L1-L2-L3-Y.
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: March 30, 2021
    Assignee: NBE-THERAPEUTICS AG
    Inventors: Ulf Grawunder, Roger Renzo Beerli
  • Method of producing an immunoligand/payload conjugate
    Patent number: 10864277
    Abstract: The present invention relates to a method of producing an immunoligand/payload conjugate, which method encompasses conjugating a payload to an immunoligand by means of a sequence-specific transpeptidase, or a catalytic domain thereof.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: December 15, 2020
    Assignee: NBE Therapeutics AG
    Inventors: Ulf Grawunder, Roger Renzo Beerli
  • Anthracycline-based antibody drug conjugates having high in vivo tolerability
    Patent number: 10758556
    Abstract: The present invention relates to antibody drug conjugates (ADCs) presenting improved properties of in vivo tolerability.
    Type: Grant
    Filed: August 6, 2019
    Date of Patent: September 1, 2020
    Assignee: NBE-THERAPEUTICS AG
    Inventors: Ulf Grawunder, Roger Beerli, Remy Gebleux
  • ROR1 antibody compositions and related methods
    Patent number: 10618959
    Abstract: The invention provides antibodies, antibody drug conjugates, antibody-based fragments or antibody fragments (antigen-binding fragments), as well as antibody drug conjugates (ADCs) and chimeric antigen receptors (CARs), that specifically recognize human ROR1 and related compositions. Also provided in the invention are methods of using such antibodies in various diagnostic and therapeutic applications.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: April 14, 2020
    Assignees: NBE-Therapeutics AG, The Scripps Research Institute
    Inventors: Christoph Rader, Haiyong Peng, Roger Beerli, Lorenz Waldmeier, Ulf Grawunder
  • Binding protein drug conjugates comprising anthracycline derivatives
    Patent number: 10517959
    Abstract: The present invention relates to an anthracycline (PNU) derivative conjugate comprising a derivative of the anthracycline PNU-159682 having the formula (i) or formula (ii) which further comprises a linker structure X-L1-L2-L3-Y.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: December 31, 2019
    Assignee: NBE-THERAPEUTICS AG
    Inventors: Ulf Grawunder, Roger Renzo Beerli
  • METHOD OF PRODUCING AN IMMUNOLIGAND/PAYLOAD CONJUGATE
    Publication number: 20190262461
    Abstract: The present invention relates to a method of producing an immunoligand/payload conjugate, which method encom passes conjugating a payload to animmunoligand by means of a sequence-specific transpeptidase, or a catalytic domain thereof.
    Type: Application
    Filed: November 21, 2017
    Publication date: August 29, 2019
    Applicant: NBE Therapeutics AG
    Inventors: Ulf Grawunder, Roger Renzo Beerli
  • ANTI-MESOTHELIN ANTIBODIES
    Publication number: 20190112385
    Abstract: The present invention relates to a human or humanized antibody, or an antibody-based binding protein, modified antibody format retaining target binding capacity, antibody derivative or fragment retaining target binding capacity, which targets Mesothelin (MN). It further relates to bi- or multispecific antibodies, to Immunoligand-Drug Conjugates, to Chimeric Antigen Receptors and to T-cells comprising such Chimeric Antigen Receptors.
    Type: Application
    Filed: October 31, 2016
    Publication date: April 18, 2019
    Applicant: NBE-THERAPEUTICS AG
    Inventors: Ina HELLMANN, Lorenz WALDMEIER, Ulf GRAWUNDER, Roger BEERLI
  • Binding protein drug conjugates comprising anthracycline derivatives
    Patent number: 10188745
    Abstract: The present invention relates to an anthracycline (PNU) derivative conjugate comprising a derivative of the anthracycline PNU-159682 having the formula (i) or formula (ii) which further comprises a linker structure X-L1-L2-L3-Y.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: January 29, 2019
    Assignee: NBE-THERAPEUTICS AG
    Inventors: Ulf Grawunder, Roger Renzo Beerli
  • Method of producing an immunoligand/payload conjugate
    Patent number: 9872923
    Abstract: A method of producing an immunoligand/payload conjugate can encompass conjugating a payload to an immunoligand by means of a sequence-specific transpeptidase, or a catalytic domain thereof.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: January 23, 2018
    Assignee: NBE THERAPEUTICS AG
    Inventors: Ulf Grawunder, Roger Renzo Beerli
  • BINDING PROTEIN DRUG CONJUGATES COMPRISING ANTHRACYCLINE DERIVATIVES
    Publication number: 20170360953
    Abstract: The present invention relates to an anthracycline (PNU) derivative conjugate comprising a derivative of the anthracycline PNU-159682 having the formula (i) or formula (ii) which further comprises a linker structure X-L1-L2-L3-Y.
    Type: Application
    Filed: December 23, 2015
    Publication date: December 21, 2017
    Applicant: NBE-Therapeutics AG
    Inventors: Ulf Grawunder, Roger Renzo Beerli
  • METHOD OF PRODUCING AN IMMUNOLIGAND/PAYLOAD CONJUGATE
    Publication number: 20160136298
    Abstract: A method of producing an immunoligand/payload conjugate can encompass conjugating a payload to an immunoligand by means of a sequence-specific transpeptidase, or a catalytic domain thereof.
    Type: Application
    Filed: March 14, 2014
    Publication date: May 19, 2016
    Applicant: NBE Therapeutics AG
    Inventors: Ulf GRAWUNDER, Roger Renzo BEERLI